B+
Bull case
30%
Probability
Target price
$125.00
Analysis reference price unavailable
Analysis 2026-09-07 · RankAlpha Sentiment Codex
HALO
Halozyme TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Record royalty growth, raised 2026 guidance, collaboration momentum, and substantial share repurchases support a positive operating thesis. The platform's value could compound if new partner programs launch successfully.
Posture
Mixed
Lead driver
Value
What changed
6 setup hits (3d) with net bullish as of 2026-10-30.
What can break
CEO Form 4 filings show open-market sales on August 17-18; this is a sentiment signal only and not evidence about operating results [#SEC-FORM4-2026-08-19].
Momentum
98
Value
63
Sentiment
39
Setup hits (3d)
6 · Net Bullish
AI TargetsBase $105.00 · Bull $125.00 · Bear $85.00Analysis 2026-09-07; returns require an exact persisted reference.
Earnings
2026-11-05 · AMC
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-30 • Vendor: Data Vendor v1
Scores
As of 2026-10-30 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-07 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-30
Investment thesis
As of 2026-10-30
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-30. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bullish
Target $108.78
Why
Momentum98 · Δ7d -0.1
Value63 · Δ7d -0.1
Sentiment39 · Δ7d +0.3
So what
Balanced signals (Net Bullish). Wait for confirmation before sizing up.
Confirming evidence
- • 6 setup hits (3d) with net bullish as of 2026-10-30.
- • Next scheduled catalyst: earnings 2026-11-05 · AMC.
- • Value remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • CEO Form 4 filings show open-market sales on August 17-18; this is a sentiment signal only and not evidence about operating results [#SEC-FORM4-2026-08-19].
- • Expectations risk: the stock is above the available analyst median target, with target breadth and revision data unavailable.
- • The Q2 beat and guidance raise appear substantially reflected in the price, while long-dated collaboration opportunities depend on partner development, regulatory approvals, launches, and continued deal cadence.
Catalyst clock
2026-11-05 · AMC
Q2 2026 beat and raised guidance [#SEC-8K-2026-08-06]
Lead driver: Value · See fundamentals
Momentum
98
8% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
+4.8
Value
63
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-1.5
Sentiment
39
45% active weight
Current posture
7d trendFlat
Δ7d
+0.3
Δ21d
-18.3
Why this grade
Composite grade C. Momentum 97.6 / Value 63.3 / Sentiment 39.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-07. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$105.00
Analysis reference price unavailable
Analysis 2026-09-07 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$85.00
Analysis reference price unavailable
Analysis 2026-09-07 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-30
Fundamentals (TTM)
As of 2026-10-30
Market Cap
$14.86B
Beta
0.97
Shares Out
113.5M
P/E (TTM)
15.0
P/S (TTM)
6.74
P/FCF (TTM)
13.90
Rev YoY
+47.7%
EPS YoY
+42.6%
Gross Margin
+76.4%
Op Margin
+56.8%
Net Debt
$2.03B
Current Ratio
2.71
As of 2026-10-30 • Updated nightlySource: Internal modelMethods & Data